New Oral Options for Diabetic Dyslipidemia Management

1.50 CME
$0 FEE
endo cme oral options


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Esperion Therapeutics.

Activity Description

Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD), which is the leading cause of death in the US, claiming over 800,000 lives annually. While many patients with elevated low-density lipoprotein cholesterol (LDL-C) benefit from statin therapy, about 10-30% suffer from statin intolerance or dose-limiting toxicities, which leaves them at risk for adverse cardiovascular events. To address this problem, expert clinicians will conduct an educational activity in conjunction with the 2020 American Diabetes Association conference for internists, endocrinologists, and diabetologists that details the latest therapeutic options for reducing LDL-C in patients with diabetes.

Target Audience

The intended audience for this activity is endocrinologists, diabetologists, cardiologists, internists, and other health care professionals involved in the management of patients with dyslipidemia.

Learning Objective

Upon successful completion of this activity, participants should be better able to:

  • Review the interplay between insulin resistance and dyslipidemia as well as the implications for patients.
  • Compare the mechanisms of action of new, oral therapies for LDL-C reduction to those of established therapies.
  • Examine the potential benefit of fixed-dose combination therapies on adherence.
  • Identify patients with diabetes with elevated LDL-C despite maximally-tolerated statin dose who may benefit from further LDL-C reduction with new options.

Activity Chair

Christie M. Ballantyne, MD
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine, Baylor College of Medicine
Houston, TX


Medical Director / President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Erin D. Michos, MD, MHS
Associate Professor of Medicine (Cardiology)
Director of Women's Cardiovascular Health
Johns Hopkins University School of Medicine
Baltimore, MD


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Ronald A. Codario, Jr., MD


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, June 30, 2020, through June 29, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s)

Christie M. Ballantyne, MD
Consulting Fee: Abbott Diagnostics, Akcea, Amarin, Amgen, Arrowhead, AstraZeneca, Corvidia, Denka Seiken, Esperion, Gilead, Janssen, Matinas BioPharma, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostics, Sanofi-Synthelabo
Contracted Research (Paid to institution): Abbott Diagnostics, ADA, AHA, Akcea, Amgen, Esperion, NIH, Novartis, Regeneron, Roche Diagnostics

Consulting Fee: Amarin, Esperion, Gelesis, Matinas
Speakers Bureau Details: Amarin, Esperion
Contracted Research: Acasti, Akcea, Alere, Allergan, Alon MedTech/Epitomee, Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, ChromaDex, CiVi, Dr. Reddy's, Esperion, Evidera, Gan & Lee, GlaxoSmithKline, Home Access, Ionis, iSpecimen, Janssen, Johnson and Johnson, LIB Therapeutics, Lilly, MedImmune, Merck, Necktar, Novartis, NovoNordisk, Omthera, Pfizer, Qualigen, Regeneron, Sanofi, Selecta, Takeda, The Medicines Company, TIMI, Urovant

Erin D. Michos, MD, MHS
No relevant financial relationships to disclose.

Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at